Therapeutic Advances in Musculoskeletal Disease最新文献

{"title":"Bone metabolism and inflammation drive structural damage in rheumatoid arthritis: clustering and multivariable analysis.","authors":"Francesco Pollastri, Ombretta Viapiana, Davide Gatti, Angelo Fassio, Camilla Benini, Carmela Dartizio, Isotta Galvagni, Valeria Messina, Maurizio Rossini, Giovanni Adami","doi":"10.1177/1759720X261433255","DOIUrl":"10.1177/1759720X261433255","url":null,"abstract":"<p><strong>Background: </strong>Rheumatoid arthritis (RA) is characterized by synovial inflammation leading to joint damage, periarticular bone loss, and systemic osteoporosis. While inflammation is a primary driver of structural damage, dysregulation of the Wnt signaling pathway, particularly through inhibitors such as Dickkopf-1 (Dkk1) and sclerostin, has been implicated in RA-associated bone loss.</p><p><strong>Objectives: </strong>Our study investigated factors associated with erosive RA, focusing on bone turnover markers and modulators of the Wnt system.</p><p><strong>Design: </strong>We performed a cross-sectional study of stable conventional synthetic disease-modifying anti-rheumatic drug (csDMARDs) in RA patients naïve to biologic DMARDs.</p><p><strong>Methods: </strong>Clinical, radiographic, and bone mineral density (BMD) data were collected. Serum markers of bone turnover, including Dkk1, sclerostin, C-terminal telopeptide of type I collagen (CTX), procollagen type 1 N-terminal propeptide (P1NP), parathyroid hormone, and vitamin D, were analyzed. Principal component analysis (PCA) and <i>k</i>-means clustering were applied to identify variable associations, and regression models were used to assess their cross-sectional associations with radiographic damage.</p><p><strong>Results: </strong>Sixty-two RA patients were included in the study. The Sharp van der Heijde score (SvdHS) was positively correlated with measures of disease activity, glucocorticoid use, anti-citrullinated protein antibodies (ACPA) titer, rheumatoid factor, C-reactive protein, Dkk1 levels, and CTX. P1NP was inversely associated with SvdHS. PCA identified three clusters related to disease activity measures, BMD, and markers of bone metabolism. Dkk1 was linked to ACPAs and osteoclastic activity, suggesting a role in bone loss.</p><p><strong>Conclusion: </strong>Our findings confirm the role of inflammation and autoantibodies in RA-related joint damage. We found that BMD and markers of bone metabolism were additional contributors. There is a complex interplay between inflammation, bone metabolism, and structural deterioration in RA.</p>","PeriodicalId":23056,"journal":{"name":"Therapeutic Advances in Musculoskeletal Disease","volume":"18 ","pages":"1759720X261433255"},"PeriodicalIF":3.3,"publicationDate":"2026-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13110286/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147781926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum interleukin-8 levels relate to disease activity in patients with rheumatoid arthritis.","authors":"Diamela León-Cabrera, Juan C Quevedo-Abeledo, Cristina Almeida-Santiago, Enrique García-Barrera, Luisa M Villar, Patricia Quiroga-Colina, Javier Gonzalo Ocejo-Vinyals, Alberto Javier-Ormazábal, Miguel Á González-Gay, Iván Ferraz-Amaro","doi":"10.1177/1759720X261436835","DOIUrl":"10.1177/1759720X261436835","url":null,"abstract":"<p><strong>Background: </strong>Interleukin 8 (IL-8) is a chemokine involved in the pathogenesis of rheumatoid arthritis (RA). However, the clinical significance of its circulating levels remains poorly defined, partly due to technical challenges in measuring IL-8 in serum. Consequently, data on the relationship between serum IL-8 concentrations and specific disease manifestations in RA are limited.</p><p><strong>Objective: </strong>In this study, we aimed to investigate the associations between serum IL-8 levels and clinical, serological, and cardiovascular features in patients with RA.</p><p><strong>Design: </strong>Cross-sectional study.</p><p><strong>Methods: </strong>A total of 216 RA patients were recruited. They underwent comprehensive evaluations, including disease-related characteristics and disease activity indices. Moreover, complete lipid profile, insulin resistance indices, metabolic syndrome criteria, and carotid ultrasound for carotid stiffness, intima-media thickness and carotid plaque detection were assessed. The SCORE2 -Systemic Cardiovascular Risk Estimation- was also calculated. IL-8 serum levels were measured using Simoa (Single Molecule Array) technique. A multivariable linear regression analysis was performed to examine the associations between disease characteristics and IL-8.</p><p><strong>Results: </strong>C-reactive protein and IL-6 were significantly associated with higher IL-8 levels after multivariable adjustment. Likewise, disease activity scores were independently and positively correlated with higher serum IL-8 concentrations after adjustment for covariates. In contrast, rheumatoid factor and anti-citrullinated protein antibodies positivity showed no association with IL-8 levels. With respect to cardiovascular features, higher SCORE2 and carotid intima media thickness values were positively related to increased IL-8 concentrations.</p><p><strong>Conclusion: </strong>Serum IL-8 levels are independently and positively associated with disease activity scores in patients with RA. These findings suggest that IL-8 may have potential as a biomarker in this population but requires prospective validation and comparison with standard markers. The observed relationship between IL-8 levels and the SCORE2 risk calculator suggests a potential association between IL-8 and cardiovascular disease.</p>","PeriodicalId":23056,"journal":{"name":"Therapeutic Advances in Musculoskeletal Disease","volume":"18 ","pages":"1759720X261436835"},"PeriodicalIF":3.3,"publicationDate":"2026-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13110282/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147782050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnosis and therapeutic management of psoriatic arthritis: summary of 2024 update of the Spanish clinical practice guideline (ESPOGUIA).","authors":"Julio Ramírez, Clementina López-Medina, Carlos Montilla, Mireia Moreno, Manuel J Moreno, Victoria Navarro, David Díaz, Agnès Fernández-Clotet, Josep Riera-Monroig, Petra Díaz-Del Campo, Juan D Cañete, Rubén Queiro","doi":"10.1177/1759720X261436463","DOIUrl":"10.1177/1759720X261436463","url":null,"abstract":"<p><p>Psoriatic arthritis (PsA) is a heterogeneous chronic inflammatory disease affecting peripheral and axial joints, entheses, skin, and nails, requiring coordinated multidisciplinary management. Since the 2018 edition of ESPOGUÍA, significant advances-including the availability of IL-17A/F, IL-23, and JAK inhibitors, as well as emerging evidence regarding axial PsA-have prompted the need for an updated guideline. The 2024 ESPOGUÍA provides evidence-based recommendations for the diagnosis and management of PsA, integrating multidisciplinary collaboration, active nursing participation, lifestyle counseling, and specific considerations for axial disease. A panel comprising rheumatologists, dermatologists, gastroenterologists, ophthalmologists, nurses, methodologists, and patient representatives formulated clinical questions using the Population, Intervention, Comparator, and Outcomes (PICO) framework. Systematic literature reviews were performed, and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was applied to critically assess the quality of evidence and guide the formulation of recommendations. The guideline emphasizes early intervention and the appropriate use of conventional synthetic DMARDs, biologic therapies, and JAK inhibitors across different disease domains, including the management of extra-musculoskeletal manifestations. Lifestyle measures, such as smoking cessation and weight management, are highlighted due to their demonstrated impact on disease activity and long-term outcomes. The essential role of specialized rheumatology nurses in patient education, treatment adherence, and counseling on modifiable risk factors is also underscored. ESPOGUÍA 2024 provides a comprehensive, multidisciplinary, and patient-centered framework for PsA management, including axial involvement, and identifies persistent gaps in early diagnosis, biomarker development, and long-term outcomes, thereby outlining priorities for future research.</p>","PeriodicalId":23056,"journal":{"name":"Therapeutic Advances in Musculoskeletal Disease","volume":"18 ","pages":"1759720X261436463"},"PeriodicalIF":3.3,"publicationDate":"2026-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13100372/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147781938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reconciling conflicting challenges in older rheumatology patients: remedies from geriatric-rheumatology clinics.","authors":"Justin Levinson, Sarah B Lieber, Namrata Singh, Devyani Misra","doi":"10.1177/1759720X261439758","DOIUrl":"10.1177/1759720X261439758","url":null,"abstract":"","PeriodicalId":23056,"journal":{"name":"Therapeutic Advances in Musculoskeletal Disease","volume":"18 ","pages":"1759720X261439758"},"PeriodicalIF":3.3,"publicationDate":"2026-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13100418/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147781923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Associations of muscle mass, adipose tissue mass, and skeletal muscle radiodensity with disease activity in axial spondyloarthritis.","authors":"Ran Cui, Xin-Yu Song, Jian-Yong Wei, Wen-Li Zhou, Yi-Li Tao, Xiao-Er Wei, Zhiyong Chen, Sheng-Ming Dai","doi":"10.1177/1759720X261442029","DOIUrl":"10.1177/1759720X261442029","url":null,"abstract":"<p><strong>Background: </strong>Body composition is increasingly recognized as an important modulator of chronic inflammation. However, the association between body composition parameters and disease activity in axial spondyloarthritis (axSpA) remains to be clearly established.</p><p><strong>Objectives: </strong>We aimed to investigate the association between muscle, subcutaneous fat composition assessed via computed tomography (CT) imaging, and disease activity in patients with axSpA.</p><p><strong>Design: </strong>This is a retrospective data registry observational study.</p><p><strong>Methods: </strong>This study analyzed 215 patients with axSpA. Body composition parameters were measured from pelvic CT scans. Parameters included the total adipose tissue volume to total skeletal muscle volume ratio (TATV/TSMV), a single-slice subcutaneous adipose tissue to skeletal muscle area ratio (SAT/SM), and skeletal muscle (SM) radiodensity. Disease activity was evaluated using the Ankylosing Spondylitis Disease Activity Score (ASDAS). Associations were analyzed using multivariate linear regression and restricted cubic splines (RCS). The probability of achieving major improvement (MI, ΔASDAS 2.0) was compared using Kaplan-Meier analysis.</p><p><strong>Results: </strong>After adjusting for age, sex, and disease duration, a higher TATV/TSMV ratio, rather than the single-slice SAT/SM ratio, was independently associated with increased ASDAS-C-reactive protein (β = 0.722, 95% confidence interval (CI): 0.215-1.231, <i>p</i> = 0.004). SM radiodensity showed an inverse, nonsignificant association (<i>p</i> = 0.48). RCS analysis identified a threshold effect of the TATV/TSMV ratio on disease activity at 0.65 (nonlinear <i>p</i> = 0.045). Above this threshold, a higher ratio was significantly associated with elevated ASDAS-CRP (hazard ratio (HR) = 3.64, 95% CI: 1.13-11.71, <i>p</i> = 0.029). Patients with a ratio <0.65 had a significantly higher probability of achieving MI (HR = 1.64, 95% CI: 1.04-2.59, log-rank <i>p</i> = 0.04).</p><p><strong>Conclusion: </strong>The pelvic TATV/TSMV ratio is an independent imaging biomarker associated with higher disease activity and lower odds of clinical improvement in patients with axSpA. A cut-off value of 0.65 may be a promising tool for risk stratification in clinical practice.</p>","PeriodicalId":23056,"journal":{"name":"Therapeutic Advances in Musculoskeletal Disease","volume":"18 ","pages":"1759720X261442029"},"PeriodicalIF":3.3,"publicationDate":"2026-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13100450/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147781913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of achieving simple disease activity index remission on joint space outcomes progression in early rheumatoid arthritis: an exploratory study using high-resolution peripheral quantitative computed tomography.","authors":"Qihan Wu, Ho So, Isaac T Cheng, Yingzhao Jin, Sze-Lok Lau, Tin-Yuet Chan, Evelyn Chow, Ling Qin, Vivian W Hung, James F Griffith, Kitty Kwok, Isaac Yim, Shirley Ying, Ka Lai Violet Lee, Jack J W Lee, Lai-Shan Tam","doi":"10.1177/1759720X261439714","DOIUrl":"10.1177/1759720X261439714","url":null,"abstract":"<p><strong>Background: </strong>Rheumatoid arthritis is a chronic inflammatory disease with progressive joint destruction resulting in functional loss. High-resolution peripheral quantitative CT (HR-pQCT) is a novel technique for detailed volumetric assessment of joint space morphology and bone erosions. We hypothesized that effective control of inflammation in early rheumatoid arthritis (ERA) patients who can achieve sustained simple disease activity index (SDAI) remission will have less progression of joint damage and functional loss than patients who cannot achieve sustained SDAI remission (SDI).</p><p><strong>Objectives: </strong>To elucidate the effects of achieving SDI on the progression of joint space outcomes in patients with ERA assessed using HR-pQCT.</p><p><strong>Design: </strong>This was a prospective study with 109 participants receiving 1-year tight-control treatment aiming at SDAI remission.</p><p><strong>Methods: </strong>A total of 109 patients received 1-year tight-control treatment aiming at SDAI remission. SDI was defined as achieving SDAI remission at months 6, 9, and 12. The primary outcome was the change in joint space size and volume at metacarpophalangeal joints 2-4, determined using HR-pQCT at 12 months.</p><p><strong>Results: </strong>At 12 months, HR-pQCT image analysis showed that 14 out of 109 (12.8%) patients achieved SDI (SDI group). No significant differences in changes in joint space and erosion parameters were observed between the SDI and non-SDI groups. Erosion volume was reduced significantly in both groups. While new erosions (0% vs 16%, <i>p</i> = 0.338) and erosion progression (0% vs 27.3%, <i>p</i> = 0.592) were only observed in the non-SDI group, partial erosion healing was numerically more frequently observed in the SDI group (27.3% vs 10.3%, <i>p</i> = 0.260). At baseline, disease activity parameters were positively correlated with joint space parameters, while after 12 months, a negative correlation emerged between disease activity parameters and both mean joint space width (JSW) and minimum JSW.</p><p><strong>Conclusion: </strong>Although HR‑pQCT did not show a significant difference in joint damage progression at 12 months between patients with and without sustained remission, the overall cohort-managed with a tight-control strategy targeting SDAI remission-exhibited minimal bone and joint damage progression over 1 year.</p>","PeriodicalId":23056,"journal":{"name":"Therapeutic Advances in Musculoskeletal Disease","volume":"18 ","pages":"1759720X261439714"},"PeriodicalIF":3.3,"publicationDate":"2026-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13070176/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147676883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plain Language Summary of a Phase 2 Study of Triamcinolone Acetonide Extended-Release for Pain Relief in People With Knee Osteoarthritis and Type 2 Diabetes.","authors":"Andrew I Spitzer, Helena Rodbard","doi":"10.1177/1759720X261433612","DOIUrl":"10.1177/1759720X261433612","url":null,"abstract":"<p><p>What is this summary about? This plain language summary of publications outlines 2 publications that represent 2 separate analyses of a single study of triamcinolone acetonide extended-release (TA-ER). TA-ER is an injection into the knee joint approved to treat osteoarthritis knee pain. The study compared the effects of TA-ER versus a standard form of the steroid triamcinolone acetonide (called triamcinolone acetonide crystalline suspension [TAcs]) on blood glucose levels in participants with knee osteoarthritis and type 2 diabetes. What were the main results? Participants with knee osteoarthritis and type 2 diabetes who received an injection of TA-ER had smaller increases in blood glucose levels than participants who received TAcs, especially in the first 3 days after injection. TA-ER also caused fewer spikes in blood glucose levels in participants compared with TAcs. No serious side effects were reported for either TA-ER or TAcs. What do the results mean? These results are important because there is an unmet need for effective pain relief options for people with knee osteoarthritis who also have type 2 diabetes. Standard steroid treatments can raise blood glucose levels, making them potentially problematic for this group. Who might find this summary helpful? The purpose of this plain language summary of publications is to provide information from recent research to people with knee osteoarthritis and type 2 diabetes who may require an injection into the knee joint or who may receive an injection of TA-ER for treatment of knee osteoarthritis. It is also intended to help healthcare professionals understand findings from recent research, supporting TA-ER as potentially more favorable versus standard steroids for patients with both knee osteoarthritis and type 2 diabetes. Who should read this summary? People who may find this summary helpful are those living with knee osteoarthritis and type 2 diabetes and their families, patient advocates, patient groups, and the healthcare professionals who treat them. Who sponsored this study? Pacira BioSciences, Inc. (formerly Flexion Therapeutics; telephone number: 844-353-9466) sponsored this study. When was this plain language summary of publications written? This summary was drafted in April-May 2025. Disclaimers ● TA-ER is approved to treat osteoarthritis knee pain. ● Researchers must look at the results of many types of studies to understand whether a study drug works, how it works, and whether it is safe to prescribe to patients. ● This plain language summary of publications outlines 2 publications based on separate analyses of a single study. The results of that single study may be different from results of other studies.</p>","PeriodicalId":23056,"journal":{"name":"Therapeutic Advances in Musculoskeletal Disease","volume":"18 ","pages":"1759720X261433612"},"PeriodicalIF":3.3,"publicationDate":"2026-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13070166/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147676865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Natural language processing to intercept rheumatoid and psoriatic arthritis from clinical notes in the Emergency Department.","authors":"Antonio Tonutti, Pierandrea Morandini, Cosimo Faeti, Nicoletta Luciano, Saverio D'Amico, Antonio Voza, Victor Savevski, Carlo Selmi","doi":"10.1177/1759720X261431361","DOIUrl":"10.1177/1759720X261431361","url":null,"abstract":"<p><strong>Background: </strong>Underdiagnosis and delayed diagnosis of rheumatoid (RA) and psoriatic arthritis (PsA) remain major concerns, causing untimely treatments and impacting outcomes.</p><p><strong>Objective: </strong>We hypothesize that natural language processing (NLP) may identify red flags from clinical notes in non-specialist settings during early disease phases, thereby improving patient referral.</p><p><strong>Design and methods: </strong>Patients diagnosed with RA or PsA were retrospectively reviewed. Clinical notes from Emergency Department visits occurring in the 12 months prior to the diagnosis were analyzed through NLP into a final classification layer. Propensity score-matched controls without arthritis accessing the same Emergency Department were selected for comparison.</p><p><strong>Results: </strong>Among 650 patients with inflammatory arthritis seeking emergency evaluations in the 12 months before the diagnosis, 294 (45.2%) had PsA and 356 (54.8%) had RA. NLP achieved modest performance in training (AUC_ROC 70% for RA and 69% for PsA) with a marked drop in independent test sets (AUC_ROC 62% and 61%, respectively), suggesting limited robustness and accuracy for routine clinical use. Further analysis suggested an overlap between terms included in notes of cases classified correctly versus incorrectly. Manual selection of notes suggestive of arthritis by Rheumatologists did not improve the model performance, which remained of limited generalizability. NLP identified demographic and clinical peculiarities of RA and PsA patients presenting to the Emergency Department, including differing temporal trends of admission between the diseases.</p><p><strong>Conclusion: </strong>While NLP showed potential for extracting disease-related signals from Emergency Department clinical notes, its current performance does not support day-to-day clinical implementation. These findings highlight the need for enhanced data quality, interpretability, and algorithm robustness. NLP provided insights into the characteristics of patients seeking emergency care during prodromal phases of RA and PsA.</p>","PeriodicalId":23056,"journal":{"name":"Therapeutic Advances in Musculoskeletal Disease","volume":"18 ","pages":"1759720X261431361"},"PeriodicalIF":3.3,"publicationDate":"2026-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13051175/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147634387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety of intravenous neridronate in pediatric patients: insights from the monocentric retrospective NAPOLEON cohort.","authors":"Stefania Costi, Andrea Amati, Raffaele Di Taranto, Francesco Baldo, Chiara Crotti, Michela Ricci, Teresa Giani, Maurizio Virgilio Gattinara, Massimo Varenna, Roberto Caporali, Cecilia Beatrice Chighizola, Achille Marino","doi":"10.1177/1759720X261419235","DOIUrl":"10.1177/1759720X261419235","url":null,"abstract":"<p><strong>Background: </strong>Evidence on the safety of intravenous neridronate (IV NER) in children with conditions other than osteogenesis imperfecta (OI) remains limited. This retrospective study describes adverse events, including acute phase reactions (APR) and hypocalcemia, over a median follow-up of 20 months in a monocentric pediatric cohort with rheumatological conditions.</p><p><strong>Methods: </strong>Thirty-seven children with OI and other bone diseases undergoing infusion of IV NER were included. Clinical, demographic, and serologic data were recorded.</p><p><strong>Results: </strong>The most common side effect was APR (62%), which occurred less frequently in patients on chronic oral cholecalciferol supplementation: 43% of the 14 patients who did not experience APR were supplemented, while none of the 23 subjects who developed APR received supplementation (<i>p</i> = 0.001). Conversely, pre-infusion 25-dihydroxycholecalciferol and calcium levels did not differ between patients who experienced APR and patients without APR (24.23 ± 12.96 vs 27.56 ± 11.81 ng/mL, respectively; <i>p</i> = 0.496). Premedication with prednisone does not seem to be effective in the prevention of APR. Hypocalcemia was rare and asymptomatic in all cases.</p><p><strong>Conclusion: </strong>NER appears safe across different pediatric conditions, with predictable first-infusion reactions. The role of vitamin D and premedication in children candidate to NER infusion should be further confirmed in larger cohorts.</p>","PeriodicalId":23056,"journal":{"name":"Therapeutic Advances in Musculoskeletal Disease","volume":"18 ","pages":"1759720X261419235"},"PeriodicalIF":3.3,"publicationDate":"2026-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13039631/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147609819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Definition of the terms used to describe psoriatic disease datasets: a HIPPOCRATES initiative.","authors":"Oliver FitzGerald, Catherine Smith, Christine Huppertz, Martin Brom, Dario Bruno, Philip S Helliwell, Marleen van de Sande, Maarten de Wit, Lars Werner, Vassilios Ioannidis, Diana Marek, Mark Ibberson, Stephen R Pennington, Michaela Koehm, Frank Behrens","doi":"10.1177/1759720X261424371","DOIUrl":"10.1177/1759720X261424371","url":null,"abstract":"<p><p>Psoriatic arthritis (PsA) is a complex, multisystem disease with no diagnostic criteria and discordant approaches to assessing disease activity and response to treatment. PsA is part of the Psoriatic Disease spectrum, encompassing cutaneous psoriasis and nail changes, PsA and in some cases, uveitis and inflammatory bowel disease. The HIPPOCRATES consortium is addressing unmet needs in PsA and has now established a harmonised data platform, the Secure HIPPOCRATES Data Management Platform (SHDMP), which will be transformative in providing researchers with the ability to interrogate at scale psoriatic disease datasets. The SHDMP datasets are diverse and include people with psoriasis being followed for the development of PsA, as well as cross-sectional, observational and randomised control trial data on people with PsA. To better understand and describe the nature of the SHDMP datasets, the HIPPOCRATES consortium has now defined and agreed on the terms that will be applied to each dataset. In this short report, the process adopted to obtain consensus on the dataset definition and the final set of terms agreed upon is described and discussed. The agreement on the terms to be used will greatly enhance a researcher's ability to select the appropriate SHDMP datasets to study.</p>","PeriodicalId":23056,"journal":{"name":"Therapeutic Advances in Musculoskeletal Disease","volume":"18 ","pages":"1759720X261424371"},"PeriodicalIF":3.3,"publicationDate":"2026-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13039602/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147609887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}